ResearcherVeterans Health AdministrationNo recent work listed
Joseph Lipscomb
Matched on ORCID iD 0000-0002-6337-7134; OpenAlex author ID A5003655579, A5111863359. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2013: 2 papers · 2014: 3 papers
Papers 5
- Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Co-author DOI 10.1002/cncr.28530↗
- Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiat… Last author DOI 10.1111/ijcp.12353↗
- The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2013.06.803↗
- The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.28047↗
- Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Last author DOI 10.1245/s10434-013-3047-x↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jerome Carl Landry · 4 shared papers, 2013–2014 · strength 0.16
- Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
- Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
- Paper Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national c… DOI 10.1245/s10434-013-3047-x↗
- David A. Kooby · 4 shared papers, 2013–2014 · strength 0.16
- Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
- Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
- Paper Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national c… DOI 10.1245/s10434-013-3047-x↗
- Theresa Wicklin Gillespie · 4 shared papers, 2013–2014 · strength 0.16
- Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
- Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
- Paper Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national c… DOI 10.1245/s10434-013-3047-x↗
- Lauren Elizabeth Colbert · 3 shared papers, 2013–2014 · strength 0.12
- Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
- Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
- Paper The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. DOI 10.1002/cncr.28047↗
- William Adrian Hall · 3 shared papers, 2013–2014 · strength 0.12
- Paper Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. DOI 10.1002/cncr.28530↗
- Paper The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. DOI 10.1016/j.ijrobp.2013.06.803↗
- Paper The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. DOI 10.1002/cncr.28047↗
- Kevin C. Ward · 1 shared paper, 2014 · strength 0.06
- Sani Haider Kizilbash · 1 shared paper, 2014 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.